Programmed death-ligand expression and lymph nodeinvolvement in penile squamous cell carcinoma

被引:0
|
作者
Peyroteo, Ines [1 ]
Santos, Filipa [2 ]
Marialva, Celso [1 ]
Ramos, Rodrigo [1 ]
机构
[1] Portuguese Inst Oncol Lisbon, Urol, Lisbon, Portugal
[2] Portuguese Inst Oncol Lisbon, Pathol, Lisbon, Portugal
关键词
PD-L1; Penile carcinoma; Lymph node involvement; Prognostic biomarker; PD-L1; EXPRESSION; ANTIBODY; SAFETY; CANCER;
D O I
10.4081/aiua.2024.12856
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Our objective was to investigate the association between programmed death-ligand (PD-L1) immunoexpression measured as a combined positive score and clinical outcomes in penile SqCC. Materials and methods: We retrospectively reviewed all penile SqCC cases diagnosed in our institution between 2018 and 2023. PD-L1 immunohistochemistry was performed as a qualitative assay. Immunoexpression in both tumor and immune cells equal or superior to 1 was considered positive. Results: A total of 34 patients with conventional penile SqCC were included. Eleven cases were HPV-associated (32.4%). Twelve cases were PD-L1 CPS < 1 and twenty-two were PD-L1 CPS >= 1. Nine cases (32.4%) were PD-L1 CPS >= 1 and p16 positive, but this did not translate in worse clinicopathological features. Larger tumors (3.0 cm in PD-L1 CPS >= 1 vs 2.5 cm in PD-L1 CPS < 1; p = 0.662), vascular invasion (36.4% in PD-L1 CPS >= 1 vs. 25.0% in PD-L1 CPS < 1; p = 0.705) and perineural invasion (40.9% in PD-L1 CPS >= 1 vs. 16.7% in PD-L1 CPS < 1; p = 0.252) were associated with PD-L1 expression. Among the high-risk features, only lymph node involvement had statistical significance, with 14 out of 22 PD-L1 CPS >= 1 patients (63.6%) having lymph node metastases when lymphadenectomy was performed (p = 0.031). With a median follow-up of 16 months (IQR 27.5), PD-L1 CPS >= 1 patients had worse overall survival (53.4 months vs 75.9 months), but no statistical significance could be inferred (p = 0.188). Conclusions: It is noteworthy the clinical significance of lymph node involvement in PD-L1 CPS >= 1 cases and a trend towards worse overall survival in this group of patients.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung
    Igarashi, Tomoyuki
    Teramoto, Koji
    Ishida, Mitsuaki
    Hanaoka, Jun
    Daigo, Yataro
    ONCOLOGY REPORTS, 2017, 38 (04) : 2189 - 2196
  • [2] Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype
    Satgunaseelan, Laveniya
    Gupta, Ruta
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    PATHOLOGY, 2016, 48 (06) : 574 - 580
  • [3] Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
    Cui, Yong-Xin
    Su, Xian-Shuang
    OPEN MEDICINE, 2020, 15 (01): : 292 - 301
  • [4] Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma
    Skala, Stephanie L.
    Liu, Tzu-Ying
    Udager, Aaron M.
    Weizer, Alon Z.
    Montgomery, Jeffrey S.
    Palapattu, Ganesh S.
    Siddiqui, Javed
    Cao, Xuhong
    Fields, Kristina
    Abugharib, Ahmed E.
    Soliman, Moaaz
    Hafez, Khaled S.
    Miller, David
    Lee, Cheryl T.
    Alva, Ajjai
    Chinnaiyan, Arul M.
    Morgan, Todd M.
    Spratt, Daniel E.
    Jiang, Hui
    Mehra, Rohit
    EUROPEAN UROLOGY FOCUS, 2017, 3 (4-5): : 502 - 509
  • [5] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [6] The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma
    Schaper, K.
    Koether, B.
    Hesse, K.
    Satzger, I.
    Gutzmer, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (05) : 1354 - 1356
  • [7] Programmed death-ligand 1 expression in the immune compartment of colon carcinoma
    Yilmaz, Osman
    Pankaj, Amaya
    Neyez, Azfar
    Rickelt, Steffen
    Taylor, Martin
    Lang, Evan R.
    Leijsen, Lieve
    Dinaux, Anne
    Shroff, Stuti G.
    Crotty, Rory
    Zhang, M. Lisa
    Cerda, Sandra
    Zhao, Qing
    Ferrone, Cristina
    Ting, David T.
    Patil, Deepa T.
    Yilmaz, Omer
    Berger, David
    Deshpande, Vikram
    MODERN PATHOLOGY, 2022, 35 (11) : 1740 - 1748
  • [8] The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma
    Akutsu, Yasunori
    Murakami, Kentaro
    Kano, Masayuki
    Toyozumi, Takeshi
    Matsumoto, Yasunori
    Takahashi, Masahiko
    Otsuka, Ryota
    Sekino, Nobufumi
    Yokoyama, Masaya
    Shiraishi, Tadashi
    Matsubara, Hisahiro
    ESOPHAGUS, 2018, 15 (02) : 103 - 108
  • [9] Programmed death-ligand 1 expression in carcinoma of unknown primary
    Kim, Hye Min
    Koo, Ja Seung
    BMC CANCER, 2024, 24 (01)
  • [10] Commentary on "Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma"
    Pena-Cardelles, Juan Francisco
    Moro-Rodriguez, Jose Ernesto
    Cebrian-Carretero, Jose Luis
    Pozo-Kreilinger, Jose Juan
    OPEN MEDICINE, 2022, 17 (01): : 227 - 228